<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01105351</url>
  </required_header>
  <id_info>
    <org_study_id>Folate Forms MTHFR</org_study_id>
    <nct_id>NCT01105351</nct_id>
  </id_info>
  <brief_title>Effect of Folic Acid on Primary Folate Forms in Relation to MTHFR</brief_title>
  <official_title>Effect of Mild Increase in Folic Acid Intake on the Distribution of Folate Forms in Relation to a Common Polymorphism in One Folate Catabolising Enzyme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saarland University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saarland University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The common polymorphism in MTHFR gene (C677T) has a significant effect on (6S)-5-CH3-H4folate
      after folic acid supplementation. For example, post supplementation differences in
      (6S)-5-CH3-H4folate between CC and TT are above 30%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators aim to test the effect of low doses of folic acid with or without B6 and
      B12 on folate forms in relation to polymorphisms in folate catabolising enzymes in elderly
      people. Our hypothesis is that differences in folate forms after folic acid supplementation
      might be due to polymorphisms in folate catabolising enzymes. Therefore, folic acid might be
      retained by people with certain genotypes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood metabolic markers</measure>
    <time_frame>18 months</time_frame>
    <description>we will measure primary folate forms after folic acid supplement</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>the Effect of MTHFR C677T on Folate Metabolism</condition>
  <arm_group>
    <arm_group_label>folic acid plus B6 and B12</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>folic 400 µg plus vitamin B12 plus B6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Folic acid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>folic acid alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>folic acid plus B6 and B12</intervention_name>
    <description>folic acid 400 µg plus vitamin B12 plus B6</description>
    <arm_group_label>folic acid plus B6 and B12</arm_group_label>
    <other_name>no further names</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>folic acid</intervention_name>
    <description>folic acid 400 µg</description>
    <arm_group_label>Folic acid</arm_group_label>
    <other_name>folic acid alone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females

          -  Age &gt; 65 years.

        Exclusion Criteria:

          -  Renal dysfunction

          -  Recent stroke, or coronary event (within the last 3 months)

          -  Current cancer treatment

          -  Antifolate (e.g. methotrexate) treatment

          -  Ileum resection

          -  Current B-vitamin supplement

          -  Epilepsy medications

          -  Megaloblastic anemia or other indications for treatment with high doses of folate or
             vitamin B12.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rima Obeid, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Chemistry, University of Saarland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Saarland</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Obeid R, Kirsch SH, Dilmann S, Klein C, Eckert R, Geisel J, Herrmann W. Folic acid causes higher prevalence of detectable unmetabolized folic acid in serum than B-complex: a randomized trial. Eur J Nutr. 2016 Apr;55(3):1021-8. doi: 10.1007/s00394-015-0916-z. Epub 2015 May 6.</citation>
    <PMID>25943647</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2010</study_first_submitted>
  <study_first_submitted_qc>April 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2010</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saarland University</investigator_affiliation>
    <investigator_full_name>Rima Obeid</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Folate</keyword>
  <keyword>MTHFR</keyword>
  <keyword>Homocysteine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

